Clinical Trial Update: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors [Phase 2, Phase 3]

View source ↗

Summary

Updates on a Phase II-III neoadjuvant trial combining toripalimab, lenvatinib, and GEMOX for resectable intrahepatic cholangiocarcinoma; study is currently acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Lenvatinib (lenvatinib)
• OXALIPLATIN (Oxaliplatin)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Intrahepatic Cholangiocarcinoma, PD1 Antibody | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING